Diabetic Macular Oedema Clinical Trial
Official title:
Diabetic Macular Oedema: the Retinal Thickness as a Function of Changes in Plasma Osmolality Evaluated by OCT.
Diabetic macular oedema is characterized by fluid accumulation in the retinal tissue from
leaking retinal vessels, the capillaries. This state can lead to severe visual loss and
blindness. According to basic physiologic rules several factors influence the fluid
transport between the capillaries and the surrounding tissue. One of these factors is the
balance between the large molecules within the vessel lumen and the retinal tissue. Some
drugs change this balance, the osmotic balance, by moving the fluid from the tissue to the
vessel lumen. In relation to diabetic macular oedema, treatment with such a drug potentially
would reduce the retinal thickness because it extracts fluid from the retinal tissue.
Glycerol has this potential. If reduction of the thickness with glycerol is confirmed, then
it proves the significance of the osmotic balance in the basic nature of diabetic macular
oedema.
In this study we therefore examine the time dependent change in retinal thickness after
glycerol intake by an instrument called optical coherence tomography (OCT). The participants
drink glycerol and the thickness of the retina is then monitored closely by OCT during the
following three hours. Since diabetic changes in the retina are focal pr. definition, the
secondary purpose of the study is to find any regional differences in the response. The
examinations are repeated at a second visit where the patient drink another dose of
glycerol, because we also want to analyse for a dose dependent response. Which dose is given
at each visit is randomised on beforehand. In addition to measuring the retinal thickness a
variety of examinations are performed both before and during the study, e.g. blood samples
and systemic blood pressure measurements.
In general, when oedema is present, increasing the osmotic pressure in the retinal
capillaries by an osmotic drug induces transcapillary fluid transport from the retinal
tissue to the vascular lumen, according to the Starling equation. Theoretically, in diabetic
macular oedema the event would lead to reduction of the retinal thickness, which could then
be visualised by Optical Coherence Tomography. The main purpose of this trial is therefore
to evaluate and quantify the changes in retinal thickness of the oedema after increasing the
intracapillary osmotic pressure with glycerol ingestion. A reduction of the retinal
thickness will confirm the application of the Starling osmotic forces on diabetic macular
oedema. Secondly, we want to describe any regional differences in the retinal response and
analyse for dose dependent variations.
Principles of material and methods: A prospective, randomized, clinical trial on 15 patients
with diabetic significant macular oedema. At baseline the patients undergo a thorough
ophthalmologic examination including ETDRS visual acuity, slit lamp biomicroscopy, Optical
Coherence Tomography (Stratus-OCT), 7-field fundus photography followed by fluorescein
angiography. In addition the systemic blood pressure is measured and blood samples are taken
to rule out severe renal insufficiency and to estimate glycosylated haemoglobin.
The patients are all randomised to drink either 1.5 or 3 mL glycerol/kg body weight (max.
250 mL pr day) on the first of two visit dates. The last dose is given at the second visit.
In the following three hours the retinal thickness is then monitored closely by Stratus-OCT
after the glycerol ingestion.
The plasma osmolality and plasma triglyceride (an indirect indicator of glycerol) are
confirmed by venous blood samples, also at predetermined times after the last swallow of
glycerol. In addition the systemic blood pressure and the capillary blood glucose are
monitored closely during the visit.
;
Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04576689 -
Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy
|
Phase 2 | |
Completed |
NCT02554747 -
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
|
N/A | |
Withdrawn |
NCT02309476 -
Sub-threshold Photocoagulation of Diabetic Macular Oedema
|
N/A | |
Terminated |
NCT02207712 -
Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
|
N/A | |
Completed |
NCT02457884 -
Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema
|
N/A | |
Completed |
NCT00148330 -
Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study
|
Phase 2/Phase 3 | |
Completed |
NCT03495765 -
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00167518 -
Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)
|
Phase 2/Phase 3 | |
Completed |
NCT01787669 -
Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
|
Phase 2 | |
Completed |
NCT01175070 -
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
|
Phase 4 | |
Terminated |
NCT00427986 -
Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema
|
N/A | |
Completed |
NCT02731911 -
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
|
||
Completed |
NCT00148265 -
A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema
|
Phase 2/Phase 3 | |
Completed |
NCT02181400 -
Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema
|
N/A |